Table 3. Measurements/indicators of pathway implementation among patients treated for rectal cancer at the Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil, 2011-2013.
| Measures/indicators | Indicator goal | % ICP within goal | ICP (n = 218) |
|---|---|---|---|
| ∆ EMR flagging - first consultation (days) | |||
| mean (SD) | ≤ 15 days | 66.3 | 12.7 (8.8) |
| 95% CI | (11.5-14.1) | ||
| median | 13.0 | ||
| ∆ first consultation - start of nCRT (days) | |||
| mean (SD) | ≤ 46 days | 67.9 | 48.4 (29.8) |
| 95% CI | (44.3-52.3) | ||
| median | 39.0 | ||
| ∆ first - last nCRT session (days) | |||
| mean (SD) | ≤ 45 days | 89.9 | 40.1 (6.7) |
| 95% CI | (39.2-41.0) | ||
| median | 39.0 | ||
| ∆ last nCRT session - surgery (weeks) | |||
| mean (SD) | ≤ 14 weeks | 75.2 | 14.8 (4.6) |
| 95% CI | (14.2-15.4) | ||
| median | 13.2 | ||
| ∆ first consultation - surgery (days) | |||
| mean (SD) | ≤ 189 days | 72.7 | 192.0 (45.8) |
| 95% CI | (185.9-198.1) | ||
| median | 177.0 | ||
| Adherence to FULV1 regimen protocol | 100% | NA | 100% |
ICP = integrated care pathway: patients were admitted between May 12, 2011, and December 31, 2013 (after implementation of the ICP); EMR = electronic medical record; NA = not applicable; nCRT = neoadjuvant chemoradiotherapy; ∆ = time interval between; 1FULV = 350 mg/m2 of 5-fluorouracil and 20 mg/m2 of leucovorin.